TY - JOUR T1 - Household transmission in people infected with SARS-CoV-2 (COVID-19) in Metropolitan Lima JF - medRxiv DO - 10.1101/2020.09.06.20189456 SP - 2020.09.06.20189456 AU - Yolanda Angulo-Bazan AU - Gilmer Solis AU - Fany Cardenas AU - Ana Jorge AU - Joshi Acosta AU - Cesar Cabezas Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/09/2020.09.06.20189456.abstract N2 - Objective Describe the characteristics of SARS-CoV-2 infection among household members with a confirmed primary case of COVID-19 in low burden districts in Metropolitan Lima.Materials and Methods A retrospective, secondary database review study was conducted. The information was collected from an epidemiological surveillance activity in close contacts (co-inhabitants) in 52 households in Metropolitan Lima with only one member with COVID-19. A reevaluation was carried out in 10 households. Epidemiological and clinical variables were evaluated and its association with the result of the rapid serological test (presence of IgG, IgM or both).Results Secondary cases were found in 40 households, which represents an average of 49.9% identification per household. A secondary attack rate of 53.0% (125 cases) was found among cohabitants, with 77.6% of cases being symptomatic (symptomatic / asymptomatic ratio: 3.5). The presence of fever and / or chills was found in 40.0% of people with a positive result, followed by a sore throat, in 39.2%. Ageusia and anosmia were present in 22.4% and 20.8% of cases, respectively. A reevaluation in 40 family members 33.6 ± 2.7 days after the first evaluation, show the persistence of positive IgM and IgG in the 20 positive cases in the first evaluation.Conclusion Having a primary case of COVID-19 in home, the secondary attack rate of this infection is 53%; however, in a significant proportion of households evaluated there was no positive case, beyond the primary case. The epidemiological and clinical characteristics found in this case were in accordance with what has already been reported in other international series.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe epidemiological activity was funded by National Institute of Health (Peru). This secondary data base study was self-funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has the approval of the Institutional Ethics Committee for Research of the National Institute of Health (Peru).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe database is not freely available for lectors, but any contact could be done sending an email to corresponsal author. ER -